Weight loss on peptide therapy is not linear, and temporary stalls of 1-3 weeks are normal even on optimal protocols
All currently approved injectable GLP-1RAs have demonstrated CV safety (non-inferiority) in CVOTs [12, 19,20,21,22,23], but only four have demonstrated both CV safety and superiority relative to standard of care [12, 20, 22, 23]
For patients on our TRT or BHRT programs, GLP-1 therapy integrates naturally into a broader metabolic optimization protocol
Call your Medicare customer service number for specific coverage details
It creates a symbiotic relationship of weight loss mechanisms that help you shed pounds consistently
For years, glucagon receptor antagonists have been favored as a treatment for both type 1 diabetes and type 2 diabetes, consistent with the idea that hepatic glucagon elevates glycemia, so blocking its effect could lower glycemia and improve glucose control